CSL Behring
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Biological: IgPro10Biological: Placebo
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- CSL Behring
- Registration Number
- NCT04138485
- Locations
- 🇺🇸
Mayo Clinic Arizona - Scottsdale, Scottsdale, Arizona, United States
🇺🇸Pacific Arthritis Care Center, Los Angeles, California, United States
🇺🇸University of California, Los Angeles, California, United States
Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Biological: IgPro20Biological: IgPro10
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 27
- Registration Number
- NCT04137224
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇩🇪Charité Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Uniklinik Köln, innere Medizin, Köln, Germany
CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
- Conditions
- Anemia, Sickle Cell
- Interventions
- Biological: Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 1
- Registration Number
- NCT04091737
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers
- Conditions
- Asthma
- Interventions
- Biological: Human beta common receptor antagonist monoclonal antibodyDrug: Placebo
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 78
- Registration Number
- NCT04082754
- Locations
- 🇩🇪
Paraxel Berlin, Berlin, Germany
🇩🇪Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM, Hannover, Germany
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 126
- Registration Number
- NCT04044690
- Locations
- 🇺🇸
8401117 - Arizona Arthritis & Rheumatology Research, Glendale, Arizona, United States
🇺🇸8401199 - Neuromuscular Research Center, Phoenix, Arizona, United States
🇺🇸8401129 - UCLA - Rheumatology Los Angeles, Los Angeles, California, United States
Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis
- Conditions
- Hidradenitis SuppurativaPalmoplantar Pustulosis
- Interventions
- Biological: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 39
- Registration Number
- NCT03972280
- Locations
- 🇦🇺
Holdsworth House Medical Practice, Darlinghurst, Australia
🇦🇺Fremantle Dermatology, Fremantle, Australia
🇦🇺The Royal Melbourne Hospital, Parkville, Australia
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
- Conditions
- Acute-graft-versus-host Disease
- Interventions
- Biological: AATBiological: Placebo
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 310
- Registration Number
- NCT03805789
- Locations
- 🇺🇸
HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States
🇺🇸Johns Hopkins Hospital, Saint Petersburg, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 11
- Registration Number
- NCT03779828
- Locations
- 🇫🇷
Hôpital Pellegrin, Bordeaux University Hospital (CHU), Bordeaux, France
🇫🇷Hôpital Henri Mondor - APHP, Créteil, France
🇫🇷Hôpital Roger Salengro - CHRU, Lille, France
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
- Conditions
- Antibody-mediated Rejection
- Interventions
- Biological: ClazakizumabDrug: Physiologic saline solution
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 194
- Registration Number
- NCT03744910
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB) - University of Alabama Hospital (UAB Hospital), Birmingham, Alabama, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Keck Medical Center Of USC, Los Angeles, California, United States
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
- Conditions
- Hereditary Angioedema
- Interventions
- Drug: PlaceboBiological: Factor XIIa antagonist monoclonal antibody
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 44
- Registration Number
- NCT03712228
- Locations
- 🇺🇸
Donald S. Levy, Orange, California, United States
🇺🇸Allergy & Asthma Clinical Research, Walnut Creek, California, United States
🇺🇸Immunoe Health Centers, Centennial, Colorado, United States